MICHAEL JAMES OVERMAN to Dose-Response Relationship, Drug
This is a "connection" page, showing publications MICHAEL JAMES OVERMAN has written about Dose-Response Relationship, Drug.
Connection Strength
0.051
-
Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008 Oct; 26(8):794-9.
Score: 0.044
-
Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity. Int J Oncol. 2000 Dec; 17(6):1077-86.
Score: 0.006